| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of ...